OpusPoint Partners
TypePrivate Equity Investment Firm
IndustryPrivate equity
Founded2009
HeadquartersNew York, NY, United States
Key people
Michael S. Weiss, Lindsay A. Rosenwald
ProductsVenture capital, Consulting
WebsiteOpusPoint

OpusPoint Partners, LLC is an investment advisory firm specializing in healthcare and life sciences.[1]

Background

Founded in 2009 by Michael S. Weiss and Lindsay A. Rosenwald, MD,[2] the firm acts as the investment manager for some portfolio private hedge funds in the healthcare and biotechnology sectors.[3]

In October 2010, OpusPoint invested approximately $3 million into National Holdings Corporation and formed a joint venture. As a result, a new investment banking firm, OPN Capital Markets, was established to leverage the resources of both companies.[4][5]

Among others, OpusPoint Partners participated in the private placement for such companies as Sunesis Pharmaceuticals, Inc. that developed Voreloxin, an anticancer drug used in acute myeloid leukemia.[6]

References

  1. ↑ "National Holdings Corporation Completes Equity Financing Led By OpusPoint Partners; Parties To Enter Into Strategic Alliance". reuters.com. 6 Oct 2010. Retrieved 2011-06-13.
  2. ↑ "OpusPoint Partners History". opuspointpartners.com. Retrieved 2011-06-13.
  3. ↑ "SECURITIES AND EXCHANGE COMMISSION (FORM 8-K)". markets.on.nytimes.com. 2011. Retrieved 2011-06-13.
  4. ↑ "National Holdings Corporation Completes Equity Financing Led By OpusPoint Partners; Parties To Enter Into Strategic Alliance". reuters.com. 6 Oct 2010. Retrieved 2011-06-13.
  5. ↑ "National Holdings Completes Equity Financing Led by OpusPoint Partners". DailyFinance.com. 6 Oct 2010. Retrieved 2011-06-13.
  6. ↑ "Sunesis Closes $28.5 Million Final Tranche of 2009 Private Placement". finance.yahoo.com. June 30, 2010. Retrieved 2011-06-13.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.